Zobrazeno 1 - 10
of 94
pro vyhledávání: '"R. Pamukcu"'
Autor:
Peter R. Holt, Christopher M. Weghorst, Thomas Delohery, N Arber, Dennis J. Ahnen, G. A. Piazza, N.-H. Kim, J. C. Reed, E. K.-H. Han, R. Pamukcu, Martin Begemann, Alessandro Sgambato, I. B. Weinstein
Publikováno v:
Gastroenterology. 113:1892-1900
BACKGROUND & AIMS: Mutations of c-K-ras occur commonly in colonic neoplasms. The aim of this study was to determine how c-K-ras mutations alter the responses to the chemopreventive agent sulindac. METHODS: The parental rat intestinal cell line IEC-18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1825bb77694184b7526b4d4498e2ff6c
https://doi.org/10.1016/s0016-5085(97)70008-8
https://doi.org/10.1016/s0016-5085(97)70008-8
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 14:213-220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2215eaa7bb122feadbc79d4eedab9baa
https://doi.org/10.1016/0731-7085(95)01631-7
https://doi.org/10.1016/0731-7085(95)01631-7
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 299(2)
These studies report on the activation and induction of cGMP-dependent protein kinase (PKG) by exisulind and analogs and test the hypothesis that PKG is involved in the induction of apoptosis in colon tumor cells. Exisulind and analogs are proapoptot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::eacda64590d00b2339df943057d409ad
https://pubmed.ncbi.nlm.nih.gov/11602670
https://pubmed.ncbi.nlm.nih.gov/11602670
Autor:
G A, Piazza, W J, Thompson, R, Pamukcu, H W, Alila, C M, Whitehead, L, Liu, J R, Fetter, W E, Gresh, A J, Klein-Szanto, D R, Farnell, I, Eto, C J, Grubbs
Publikováno v:
Cancer research. 61(10)
Exisulind (Aptosyn) is a novel antineoplastic drug being developed for the prevention and treatment of precancerous and malignant diseases. In colon tumor cells, the drug induces apoptosis by a mechanism involving cyclic GMP (cGMP) phosphodiesterase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f798659955f3b16673bf330a76401836
https://pubmed.ncbi.nlm.nih.gov/11358813
https://pubmed.ncbi.nlm.nih.gov/11358813
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(10)
Sulindac sulfone (Exisulind) induces apoptosis and exhibits cancer chemopreventive activity, but in contrast to sulindac, it does not inhibit cyclooxygenases 1 or 2. We found that sulindac sulfone and two potent derivatives, CP248 and CP461, inhibite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2dec8a1ebaf4b34fb3db4bff8afafd8f
https://pubmed.ncbi.nlm.nih.gov/11051267
https://pubmed.ncbi.nlm.nih.gov/11051267
Publikováno v:
Cancer research. 60(13)
Sulindac sulfone (exisulind), although a nonsteroidal anti-inflammatory drug derivative, induces apoptosis in tumor cells by a mechanism that does not involve cyclooxygenase inhibition. SW480 colon tumor cells contain guanosine 3',5'-monophosphate (c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2fea4d2e592ac95eede582fb5ed1b8e4
https://pubmed.ncbi.nlm.nih.gov/10910034
https://pubmed.ncbi.nlm.nih.gov/10910034
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis
Autor:
G D, Stoner, G T, Budd, R, Ganapathi, B, DeYoung, L A, Kresty, M, Nitert, B, Fryer, J M, Church, K, Provencher, R, Pamukcu, G, Piazza, E, Hawk, G, Kelloff, P, Elson, R U, van Stolk
Publikováno v:
Advances in experimental medicine and biology. 470
Sulindac sulfone (Exisulind), a metabolite of the non-steroidal anti-inflammatory drug, sulindac, was evalauted for its effects on the development of rectal polyps in patients with familial adenomatous polyposis. Three cohorts of 6 patients each were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e15d28f0689f9ff86265c1ed0d3bcf95
https://pubmed.ncbi.nlm.nih.gov/10709673
https://pubmed.ncbi.nlm.nih.gov/10709673
Autor:
E, Skopińska-Rózewska, G A, Piazza, E, Sommer, R, Pamukcu, E, Barcz, M, Filewska, W, Kupis, R, Caban, P, Rudziński, J, Bogdan, S, Mlekodaj, E, Sikorska
Publikováno v:
International journal of tissue reactions. 20(3)
The nonsteroidal antiinflammatory drug sulindac (sulfoxide) is known to cause regression and prevent recurrence of adenomas in patients with familial adenomatous polyposis. The mechanism of action does not appear to require inhibition of prostaglandi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::faecadb47e6230fe8e3e257eefa51e8c
https://pubmed.ncbi.nlm.nih.gov/9894180
https://pubmed.ncbi.nlm.nih.gov/9894180
Autor:
G A, Piazza, D S, Alberts, L J, Hixson, N S, Paranka, H, Li, T, Finn, C, Bogert, J M, Guillen, K, Brendel, P H, Gross, G, Sperl, J, Ritchie, R W, Burt, L, Ellsworth, D J, Ahnen, R, Pamukcu
Publikováno v:
Cancer research. 57(14)
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac, have cancer chemopreventive properties by a mechanism that has been suggested to involve cyclooxygenase inhibition and reduction of prostaglandin (PGE2) levels in the target tissue. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b096e78f179bd21ca756b013c67f6851
https://pubmed.ncbi.nlm.nih.gov/9230200
https://pubmed.ncbi.nlm.nih.gov/9230200
Publikováno v:
Cancer research. 57(12)
Sulindac causes regression of and prevents recurrence of colonic adenomas in patients with familial adenomatous polyposis. Although cell cycle arrest and apoptosis have been proposed, the mechanism of action is poorly understood. In this study, we ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::842cc925db0f7c0e4de8a2e1503cf0e7
https://pubmed.ncbi.nlm.nih.gov/9192825
https://pubmed.ncbi.nlm.nih.gov/9192825